Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development
A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody targeting [interleukin]-4 alpha receptor, is used for the treatment of moderate to severe [AD],” Iraj Hasan, BA, a student at the West Virginia University School of Medicine, and colleagues wrote.